Tania Diaz
Internal Medicine · Arden, NCNPI 1396181251
Payments from drug & device makers
Across 73 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$193
- Amgen$184
- Novo Nordisk$153
- Abbott$134
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$81
- Lilly USA, LLC$75
- plus $451 from 15 others
What the payments were for
- Food & beverage$1,271100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $193 |
| Amgen | 12 | $184 |
| Novo Nordisk | 10 | $153 |
| Abbott | 6 | $134 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $81 |
| Lilly USA, LLC | 4 | $75 |
| Johnson & Johnson | 4 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Evofem Biosciences, Inc. | 2 | $35 |
| GSK | 2 | $34 |
| Pfizer | 2 | $30 |
| AstraZeneca | 2 | $29 |
| Boehringer Ingelheim | 2 | $28 |
| Bayer | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Nevro Corp. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Exact Sciences | 1 | $14 |
How this compares
$1,271 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $56,760 |
| JardianceEmpagliflozin | 39 | $56,692 |
| EliquisApixaban | 33 | $41,945 |
| Repatha SureclickEvolocumab | 34 | $31,290 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $14,699 |
| SynthroidLevothyroxine Sodium | 70 | $6,882 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,565 |
| Rosuvastatin Calcium | 357 | $4,573 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,735 |
| Ezetimibe | 59 | $2,028 |
| Valsartan | 87 | $1,962 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $1,684 |
| Levothyroxine Sodium | 190 | $1,674 |
| Atorvastatin Calcium | 160 | $1,496 |
| Gabapentin | 104 | $1,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $153 | $56,76045 claims |
| Boehringer IngelheimJardiance | $28 | $56,69239 claims |
| PfizerEliquis | $30 | $41,94533 claims |
| GSKBreo Ellipta | $34 | $14,69928 claims |
| AbbVieSynthroid | $193 | $6,88270 claims |
| AstraZenecaSymbicort | $29 | $3,73517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Arden
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.